Vancouver, British Columbia, Canada, April 26, 2016, Lifestyle Delivery Systems Inc.
(CSE: LDS and OTCQB: LDSYF) (“LDS” or the “Company”) is pleased to announce that
on April 26, 2016, the Company appointed Dr. John Sanderson, MD as its Chief Science
Officer.
Dr. Sanderson’s main objectives will be to work in conjunction with researchers to
advance the development of the Company's CannaStrips technology as well as to create protocols necessary for the much anticipated clinical trials. In addition, Dr. Sanderson will work on composition of the white papers, following the results of the clinical trials,
and secure patents for the CannaStrips technology.
Dr. Sanderson is a stem cell researcher who began his career in clinical medicine
specializing in diabetes and intravenous nutrition of critically ill patients. His accolades
include receiving NIH funding, multiple issued patents and the publication of numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers
and acquisitions, formulating strategic initiatives and, evaluating new technologies. As a consultant to Fortune 100 health care companies and the U.S. government, Dr. Sanderson was instrumental in devising technological solutions to important public
health challenges such as obesity, diabetes, and asthma.
The Company’s CEO, Brad Eckenweiler, is optimistic that “the addition of Dr. Sanderson is a very significant step towards achievement of our goals. His vast knowledge and expertise will add tremendous benefit and credibility to the medical application of our CannaStrips technology and to our latest research and development efforts.”
AI
